Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.60 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.60 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.60 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.60 |
| ▸ | CA12 | O43570 | 1/20 | 0.46 |
| ▸ | CA1 | P00915 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 1/20 | 0.46 |
| ▸ | CA4 | P22748 | 1/20 | 0.46 |
| ▸ | CA7 | P43166 | 1/20 | 0.46 |
| ▸ | CA9 | Q16790 | 1/20 | 0.46 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 2/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 3/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | BLM | P54132 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1501174 | 0.83 | CA1 (0.58) | ALDH1A1TDP1ADRA2BPTGS1CA12 | |
| Ammonia Solution, Strong SCHEMBL2233000 | 0.80 | CA1 (0.55) | ALDH1A1TDP1ADRA2BPTGS1CA12 | |
| SCHEMBL363904 | 0.78 | ALDH1A1 (0.41) | ALDH1A1TDP1ADRA2BPTGS1POLB | |
| SCHEMBL27926958 | 0.77 | ALDH1A1 (0.64) | ALDH1A1TDP1ADRA2BPTGS1POLB | |
| SCHEMBL15453566 | 0.76 | CA1 (0.50) | ALDH1A1TDP1ADRA2BPTGS1CA12 | |
| SCHEMBL29726496 | 0.76 | ALDH1A1 (0.65) | ALDH1A1TDP1ADRA2BPTGS1CA12 | |
| SCHEMBL7276398 | 0.76 | ALDH1A1 (0.65) | ALDH1A1TDP1ADRA2BPTGS1CA12 | |
| SCHEMBL30816756 | 0.76 | ALDH1A1 (0.65) | ALDH1A1TDP1ADRA2BPTGS1CA12 | |
| SCHEMBL7930018 | 0.76 | CA1 (0.50) | ALDH1A1TDP1ADRA2BPTGS1CA12 | |
| SCHEMBL216473 | 0.76 | ALDH1A1 (0.65) | ALDH1A1TDP1ADRA2BPTGS1CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 330 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109153655-A | For preventing or treating the novel N- acyl urea derivatives of cardiovascular disease and comprising its composition | 高丽大学校产学协力团 | 2019-01-04 | — | — | CN | claimed |
| EP-3063136-A2 | PHENAZINE DERIVATIVES AS ANTI-CANCER AND ANTI-INFECTIVE AGENTS | Universitetet I Oslo (NO) | 2016-09-07 | — | — | EP | claimed |
| WO-2015063516-A2 | COMPOUNDS | UNIVERSITETET I OSLO (NO) | 2015-05-07 | — | — | WO | claimed |
| US-20250393467-A1 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES | UNIVERSAL DISPLAY CORPORATION (US) | 2025-12-25 | — | — | US | disclosed |
| US-20250361237-A1 | 1,4-DIHYDROBENZO[D]PYRAZOLO[3,4-F][1,3]DIAZEPINE DERIVATIVES AND RELATED COMPOUNDS AS LRRK2, NUAK1 AND/OR TYK2 KINASE MODULATORS FOR THE TREATMENT OF E.G. AUTOIMMUNE DISEASE | ORIGENIS GMBH (DE) | 2025-11-27 | — | — | US | disclosed |
| US-12410187-B2 | Fused tricyclic compounds useful as anticancer agents | ASTRAZENECA AB (SE) | 2025-09-09 | — | — | US | disclosed |
| US-12384788-B2 | 1,4-dihydrobenzo[d]pyrazolo[3,4-f][1,3]diazepine derivatives and related compounds as LRRK2, NUAK1 and/or TYK2 kinase modulators for the treatment of e.g. autoimmune disease | ORIGENIS GMBH (DE) | 2025-08-12 | — | — | US | disclosed |
| WO-2025106644-A1 | HETEROCYCLIC COMPOUNDS AS INHIBITORS OF ALPHA-V BETA-1 INTEGRIN | MORPHIC THERAPEUTIC, INC. (US) | 2025-05-22 | — | — | WO | disclosed |
| CN-119775277-A | Compounds as modulators of LRRK2, NUAK1 and/or TYK2 kinases for the treatment of, for example, autoimmune diseases | 原真股份有限公司 | 2025-04-08 | — | — | CN | disclosed |
| CN-114793435-B | Compounds as modulators of LRRK2, NUAK1 and/or TYK2 kinases for the treatment of, for example, autoimmune diseases | 原真股份有限公司 | 2024-10-01 | — | — | CN | disclosed |
| US-12060347-B2 | Bicyclic heteroaryl substituted compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-08-13 | — | — | US | disclosed |
| CN-1185227-C | Novel compounds | ASTRAZENECA AB (SE) | 2005-01-19 | — | — | CN | disclosed |
| WO-2004103996-A1 | HEPATITIS C INHIBITOR COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2004-12-02 | — | — | WO | disclosed |
| WO-2004103996-A1 | HEPATITIS C INHIBITOR COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2004-12-02 | — | — | WO | disclosed |
| EP-1242406-B1 | NOVEL COMPOUNDS | ASTRAZENECA AB (SE) | 2004-03-17 | — | — | EP | disclosed |
| CN-1434818-A | Novel compounds | ASTRAZENECA AB (SE) | 2003-08-06 | — | — | CN | disclosed |
| US-20030036552-A1 | Novel compounds | ASTRAZENECA AB (SE) | 2003-02-20 | — | — | US | disclosed |
| EP-1242406-A1 | NOVEL COMPOUNDS | AstraZeneca AB (SE) | 2002-09-25 | — | — | EP | disclosed |
| CN-1326457-A | 4-aminopyrrolopyrimidines as kinase inhibitors | BASF AG (DE) | 2001-12-12 | — | — | CN | disclosed |
| WO-2001046263-A1 | NOVEL COMPOUNDS | ASTRAZENECA AB (SE) | 2001-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12410187-B2 | Fused tricyclic compounds useful as anticancer agents | MCL1, TP53, CCNA2 | ALDH1A1 917/4885TDP1 1442/4885ADRA2B 4038/4885 |
| US-12060347-B2 | Bicyclic heteroaryl substituted compounds | F2, F2RL3, F12 | ALDH1A1 1598/4885TDP1 227/4885ADRA2B 946/4885 |
| US-20250393467-A1 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES | LBR, OXSR1, EPOR | ALDH1A1 1405/4885TDP1 3946/4885ADRA2B 531/4885 |
| US-12384788-B2 | 1,4-dihydrobenzo[d]pyrazolo[3,4-f][1,3]diazepine derivatives and related compounds as LRRK2, NUAK1 and/or TYK2 kinase modulators for the treatment of e.g. autoimmune disease | NUAK1, TYK2, MARK1 | ALDH1A1 2169/4885TDP1 440/4885ADRA2B 875/4885 |
| US-20250361237-A1 | 1,4-DIHYDROBENZO[D]PYRAZOLO[3,4-F][1,3]DIAZEPINE DERIVATIVES AND RELATED COMPOUNDS AS LRRK2, NUAK1 AND/OR TYK2 KINASE MODULATORS FOR THE TREATMENT OF E.G. AUTOIMMUNE DISEASE | NUAK1, TYK2, MARK1 | ALDH1A1 2169/4885TDP1 440/4885ADRA2B 875/4885 |
| US-20030036552-A1 | Novel compounds | ARRB1, OPRK1, OPRM1 | ALDH1A1 383/4885TDP1 2487/4885ADRA2B 31/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.